Announcements

15.01.2020

Change in the authorisation practice with regard to innovative human medicinal products for the prevention of communicable diseases

Application of Art. 13 TPA – streamlining of the review procedure for specific medicinal product categories on request

18.12.2019

Swissmedic and the Korean regulatory authority extend their cooperation in the area of therapeutic products

Swissmedic and the Korean Ministry of Food and Drug Safety (MFDS) sign an agreement on Good Manufacturing Practice

17.12.2019

ICH Assembly in Singapore, November 2019

Expert meeting adopts new Guidelines on quality and medicinal product safety

06.12.2019

Trace amounts of a nitrosamine impurity found in individual diabetes medicines

Isolated traces of the nitrosamine NDMA have been detected in individual diabetes preparations with the active substance metformin – investigations are ongoing worldwide.

03.12.2019

13 new psychoactive substances added to Narcotics List

FDHA has prompted to add substances to the Narcotics List to combat drug trafficking

29.11.2019

Aufsichtsabgabe 2019 – Selbstdeklaration

Eingabefrist: 24. Januar 2020

22.11.2019

Potential nitrosamine contamination: request to perform a risk evaluation

Marketing authorisation holders of human medicinal products asked to conduct their own evaluation of the potential risk of contamination with nitrosamines.

28.10.2019

Intensified action targeting illegally imported erectile stimulants: what they really contain

Swissmedic laboratory inspects illegal shipments of medicinal products in which tadalafil is the declared active substance

22.10.2019

Warning regarding Esillaa slimmers’ tea

Swissmedic is issuing a warning regarding the slimming product Esillaa.

15.01.2020

Change in the authorisation practice with regard to innovative human medicinal products for the prevention of communicable diseases

Application of Art. 13 TPA – streamlining of the review procedure for specific medicinal product categories on request

18.12.2019

Swissmedic and the Korean regulatory authority extend their cooperation in the area of therapeutic products

Swissmedic and the Korean Ministry of Food and Drug Safety (MFDS) sign an agreement on Good Manufacturing Practice

17.12.2019

ICH Assembly in Singapore, November 2019

Expert meeting adopts new Guidelines on quality and medicinal product safety

06.12.2019

Trace amounts of a nitrosamine impurity found in individual diabetes medicines

Isolated traces of the nitrosamine NDMA have been detected in individual diabetes preparations with the active substance metformin – investigations are ongoing worldwide.

03.12.2019

13 new psychoactive substances added to Narcotics List

FDHA has prompted to add substances to the Narcotics List to combat drug trafficking

29.11.2019

Aufsichtsabgabe 2019 – Selbstdeklaration

Eingabefrist: 24. Januar 2020

22.11.2019

Potential nitrosamine contamination: request to perform a risk evaluation

Marketing authorisation holders of human medicinal products asked to conduct their own evaluation of the potential risk of contamination with nitrosamines.

28.10.2019

Intensified action targeting illegally imported erectile stimulants: what they really contain

Swissmedic laboratory inspects illegal shipments of medicinal products in which tadalafil is the declared active substance

22.10.2019

Warning regarding Esillaa slimmers’ tea

Swissmedic is issuing a warning regarding the slimming product Esillaa.

Last modification 16.11.2017

Top of page